Yan Jin, MD

Bio

Industry experience:

• Represent Eli Lilly and Company at IQ Clinical Pharmacology Leadership Group
• Led the clinical pharmacology team during the FDA and EU submission for a monoclonocal antibody
• Designed and supervised the execution several phase 1 programs in cardiovascular, endocrine and neuroscience therapeutic areas.
• Led the design and implementation of 2 multicenter phase 2 trials
• Chair of protocol review committee for clinical pharmacology and member of internal medicine protocols.
• Member of Immunogenicity Working Group
• Scientific lead for the “DMET haplotype” project that semi-automates the translation of the DMET chip SNP data to CYP star alleles

Academic research focus:

• Clinical pharmacology and pharmacogenetics of breast cancer hormone therapy
• Clinical pharmacology and pharmacogenetics verapamil
• Clinical pharmacology and pharmacogenetics of clopidogrel antiplatelet therapy

Contribution to professional society:

• Member of Membership Action Team of ASCPT
• Reviewer of Clinical Pharmacology and Therapeutics
• Reviewer of British Journal of Clinical Pharmacology

Professional Memberships:

American Society of Clinical Pharmacology and Therapeutics

Specialty Board:

Internal Medicine: Board Certified

Clinical Pharmacology: Board Certified